# Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

Study · id `cardio:ct-nct03041259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03041259](<https://clinicaltrials.gov/study/NCT03041259>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03041259

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.

## Technical summary

Registry record NCT03041259. Randomized; single masking; primary purpose treatment. Start 2020-01 (anticipated); primary completion 2022-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT03041259, source copy `cardio:ctgov-nct03041259-2018-08-09`, retrieved 2026-10-31)
- Planned start: 2020-01 (anticipated) (ClinicalTrials.gov record NCT03041259, source copy `cardio:ctgov-nct03041259-2018-08-09`, retrieved 2026-10-31)
- Primary completion: 2022-01 (anticipated) (ClinicalTrials.gov record NCT03041259, source copy `cardio:ctgov-nct03041259-2018-08-09`, retrieved 2026-10-31)
- Completion: 2022-07 (anticipated) (ClinicalTrials.gov record NCT03041259, source copy `cardio:ctgov-nct03041259-2018-08-09`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03041259-2018-08-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
- Acronym: RESTORE
- Condition: Critical Limb Ischemia
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Rejuveinix Low Dose
- Intervention (Drug): Rejuveinix High Dose
- Lead sponsor: Reven Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 016001483dd07516ed9c2b7853ee95dd1fbdb24e7c080813aa2a9eb1594e6df9
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
